Skip to main content

Safety / Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

Trial Status: Complete

This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo. Participants who meet all eligibility criteria following the Screening / Run-In period will be randomized to 1 of 2 treatment arms; blinded Q-122 or placebo for a period of 28 days. All participants will be followed for a 2-week, drug-free, follow-up period after their last dose of blinded Q-122 / placebo before termination from the study.

Inclusion Criteria

  • Be a female, aged between 18 - 70 years on the day of informed consent.
  • Have a history of or current breast cancer and currently taking tamoxifen or an aromatase inhibitor.
  • On a stable dose of TAM or an AI for a minimum of 30 days before the Screening Visit and no anticipated need to change the dose for the duration of the study.
  • Experience an average of at least 50 moderate to severe hot flashes/week for the 2 weeks immediately preceding the Run-In Visit (i.e., during the Screening period).
  • If on thyroid medication, on a stable dose for a minimum of 30 days before the Screening Visit and no anticipated need to change the dose for the duration of the study.
  • Willing and able to complete the daily participant diary, attend all study visits, and participate in all study procedures.
  • Able to provide informed consent.

Exclusion Criteria

  • Childbearing potential, pregnancy, or lactation except in patients who are on stable dose of AI in combination with luteinizing hormone releasing hormone agonists such as Zoladex, Leuprolide (Lupron) or equivalent. Non-childbearing potential is defined as physiologically incapable of becoming pregnant by one of the following:
  • Has had a partial or complete hysterectomy or
  • Has had a bilateral oophorectomy or
  • Has had a bilateral tubal ligation or fallopian tube inserts or
  • Is post-menopausal (amenorrhea > 1 year) confirmed by levels of follicle stimulating hormone (FSH). FSH levels may be lower in menopausal women treated with tamoxifen when compared with FSH levels appropriate for confirming menopause in women not treated with tamoxifen. For those patients who are on stable dose of tamoxifen, confirmation of menopause is based on the clinical opinion of the PI and medical monitor on a 'case-by-case basis'.
  • Currently experiencing undiagnosed vaginal bleeding.
  • Women with advanced breast cancer (Stage 4).
  • Greater than 60% reduction in the frequency of moderate to severe hot flashes during the 1-week single blind Run-In period or inability to correctly record hot flashes and/or drug dosing in the participant diary.
  • Participation in another clinical or surgical trial within 30 days prior to screening or during the study without the prior written consent of the Medical Monitor.
  • Gastrointestinal, liver, kidney or other conditions which could interfere with the absorption, distribution, metabolism or excretion of Q-122 at PI discretion.
  • Untreated overt hyperthyroidism.
  • Have any other medical condition, clinically important systemic disease or significant co-morbidities or any finding during Screening that in the judgment of the investigator puts the participant at increased risk by participation in this study, or that may affect the reliability of participant diary entries.
  • Known inability to complete all study visits and study assessments for scheduling or other reasons.
  • BMI > 40 kg/m2; Participants with a BMI greater than 40 kg/m2 may be enrolled on a case-by-case basis if approved by the Medical Monitor and if the participant is not deemed at increased risk of adverse effects based on body habitus and cardiovascular health.
  • Women with a history of, or current evidence of, abuse of alcohol or any drug substance, or who regularly drink more than 3 standard drinks per day.
  • Uncontrolled systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg on 3 consecutive readings within the screening visit.
  • Abnormal laboratory findings:
  • Hemoglobin < 9.5 g/dL (g/L); or any abnormal values that are deemed clinically significant by the investigator should be discussed with the medical monitor before being deemed ineligible.
  • Fasting ALT, AST, GGT, or bilirubin greater than twice the upper limit of normal that is confirmed on a second sample.
  • <60 eGFR mL/min/1.73 m2.
  • In the opinion of the investigator, have substantial risk of disease progression within the 3 months following screening and/or who potentially may require further treatment for their breast cancer during the study period including follow-up.
  • Any other reason which in the investigator's opinion makes the participant unsuitable for a clinical trial.
  • On any medications, either prescription or over-the-counter that are being taken solely for the purpose of treating VMS including SSRI/SNRI, gabapentin or pregabalin.


Indiana University / Melvin and Bren Simon Cancer Center
Contact: Heidi Neuburger
Phone: 317-111-1111


Johns Hopkins University / Sidney Kimmel Cancer Center


Brigham and Women's Hospital
Status: ACTIVE
Contact: Hadine Joffe
Phone: 617-525-9627
Dana-Farber Cancer Institute
Status: ACTIVE

Vasomotor symptoms (VMS) are significant in postmenopausal women with the most effective

medications for relief being hormonal preparations. Non-hormonal medications have

demonstrated efficacy but at a far lower level than estrogen replacement therapy. For women

with a history of breast cancer, hormone replacement therapy is often contraindicated and is

not an option for women receiving endocrine therapy including tamoxifen (TAM) and aromatase

inhibitors (AI). Breast cancer survivors, and women receiving endocrine therapy in

particular, have a high rate of problematic hot flashes. In an open label Phase 1 study of

the safety and activity of Q-122 in breast cancer patients taking TAM or an AI, 8 of 9 women

who received at least 1 dose of 100 mg and 10 of 11 women who received at least 1 dose of 200

mg had a reduction in hot flashes of 2 or more per day, the FDA criteria for anti-VMS

activity. This study will define the effect of Q-122 versus placebo in a population of women

with a history of or current breast cancer who have an average of 50 or more moderate to

severe hot flashes per week.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Que Oncology

  • Primary ID Q122-2001
  • Secondary IDs NCI-2019-01796
  • ID NCT03518138